









Markets
/
Stocks
/
nasdaq-catx
/

Perspective Therapeutics Inc

CATX

4.710USD

+0.080+1.73%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

350.13MMarket Cap

LossP/E TTM



Perspective Therapeutics Inc

4.710

+0.080+1.73%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Perspective Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Perspective Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 74 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.25.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Perspective Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

74 / 392

Overall Ranking

195 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Perspective Therapeutics Inc Highlights

StrengthsRisks

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.45M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.45M.

Fairly Valued

The company’s latest PE is -3.15, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 43.90M shares, increasing 0.00% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 5.61K shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

12.250

Target Price

+164.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Perspective Therapeutics Inc is 5.64, ranking 341 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 209.00K, representing a year-over-year decrease of 43.36%, while its net profit experienced a year-over-year decrease of 71.73%.

Score

Industry at a Glance

Previous score

5.64

Change



Financials

6.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.86

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Perspective Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Perspective Therapeutics Inc is 7.54, ranking 106 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.15, which is -56.47% below the recent high of -1.37 and -313.67% above the recent low of -13.04.

Score

Industry at a Glance

Previous score

7.54

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Perspective Therapeutics Inc is 8.15, ranking 159 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 20.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.15

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

12.250

Target Price

+164.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Perspective Therapeutics Inc

CATX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Perspective Therapeutics Inc is 9.04, ranking 42 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.50 and the support level at 2.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.02

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.433

Buy

RSI(14)

66.785

Neutral

STOCH(KDJ)(9,3,3)

61.488

Neutral

ATR(14)

0.755

High Vlolatility

CCI(14)

60.607

Neutral

Williams %R

37.084

Buy

TRIX(12,20)

2.722

Sell

StochRSI(14)

6.664

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.940

Sell

MA10

4.060

Buy

MA20

3.308

Buy

MA50

2.878

Buy

MA100

2.987

Buy

MA200

3.154

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Perspective Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 83.07%, representing a quarter-over-quarter increase of 0.00%. The largest institutional shareholder is The Vanguard, holding a total of 3.49M shares, representing 3.06% of shares outstanding, with 25.84% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lantheus Holdings, Inc.

11.68M

Fidelity Management & Research Company LLC

5.77M

-14.58%

BlackRock Institutional Trust Company, N.A.

4.02M

+2.00%

The Vanguard Group, Inc.

Star Investors

3.44M

+4.99%

Avidity Partners Management LP

2.99M

+61.09%

Morgan Stanley & Co. LLC

2.62M

+76.33%

Millennium Management LLC

2.56M

-1.25%

Nicholson Wealth Management Group, LLC

1.62M

+0.25%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Perspective Therapeutics Inc is 2.89, ranking 188 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Perspective Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.